Note: Descriptions are shown in the official language in which they were submitted.
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
1
Compositions comprising phytoestrogens selective for estrogen beta
receptor and dietary fibres
FIELD OF INVENTION
The present invention relates to compositions comprising one or more
phytoestrogens in association with dietary fibres, insoluble and resistant to
enzymatic digestion, and to the use of said compositions for the prophylactic
and/or therapeutic treatment of intestinal mucosa and in particular of
adenopolyposis coli, and of their progression to colorectal carcinoma.
BACKGROUND OF THE INVENTION
Adenocarcinoma, or colorectal carcinoma (CRC), is the third cause of death in
the
world. CRC pathogenesis includes polyps formation onto the intestinal mucosa,
considered pre-cancerous lesions. When diagnosed by colonoscopy, the
intestinal
polyps are usually endoscopically removed. After polypectomy, the recurrence
rate
is around 10-15 % per year. Among recurrent polyps, 10% occurs as advanced
adenoma, characterised by a diameter > 1 cm and histologically villous. The
presence of one advanced adenoma, or the presence of two new formations after
polypectomy, independently from their histological characteristics,
characterise the
population with the highest risk of developing a CRC (Vogelstein B et al.
Genetic
alterations during colorectal-tumor development. NEJM 1988, 319: 525-532).
Human familial adenomatous polyposis (FAP) is caused by a germinal mutation of
the APC (Adenomatous Polyposis Coli) tumour suppressor gene. FAP is
characterised by the development of a large number (hundreds to thousands) of
adenomas in the colon. Whereas the genetic substrate favours the initiation of
the
tumorigenic process and cannot be pharmacologically or nutritionally modified,
promotion of tumorigenesis may be controlled, so thwarting the progression
toward cell de-differentiation and neoplastic transformation. The primary goal
of
the colonoscopic screening is the monitoring of adenomas and their progression
to
advanced forms and to CRC. In addition to colonoscopic screening, the clinical
need for chemopreventive interventions, safe and effective in keeping low the
recurrence rate of adenomas, is certainly high, but still unmet.
Cyclooxigenase-2
(COX-2) inhibition by celecoxib and rofecoxib, although effective, is
associated
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
2
with an unbearable risk of cardio-vascular side effects (Lance P.
Chemoprevention
of colorectal cancer: some progress but a long way to go. Gastroenterology
2008,
134: 341-343).
A higher CRC prevalence in males, and a reduced incidence in females
undergoing hormone replacement therapy (HRT) support the hypothesis that
estrogens play a protective role in colon tumorigenic process. As a further
proof of
concept of the protective role of estrogens in the intestinal mucosa, it must
be
cited the recent evidence on the regression of the adenomas in a young woman,
affected by FAP, after estro-progestinic therapy for contraceptive purposes
(Giardiello F, Hylind L, Trimbath J et al. Oral Contraceptives and Polyp
Regression
in Familial Adenomatous Polyposis. Gastroenterology 2005; 128:1077-1080).
Unfortunately, in the epidemiological studies conducted on post-menopausal
women undergoing estro-progestinic therapy, a high incidence of breast cancer
and cardiovascular accidents have been observed, thus requiring the early
termination of the study to safeguard the health of the enrolled patients
(Writing
Group for the Women's Health Initiative Investigators. Risks and benefits of
estrogen plus progestin in healthy postmenopausal women. JAMA 2002, 288: 321-
333).
Estrogen receptors exist in two forms: alpha (ERa) and beta (ER(3),
differently
localised and expressed in the various anatomical districts. ERa is mainly
localised
in breasts, cardiovascular system, bones, urogenital and central nervous
system,
whereas ER13 is expressed in prostate, salivary glands, testes, ovaries, in
the
immune system and, predominantly, in the intestine. 1713-estradiol (estrogen)
is a
non selective ligand for both receptors, that performs a proliferative
activity in
presence of ERa and anti-proliferative in presence of ER13 (Koehler KF et al.
Reflections on the discovery and significance of Estrogen Receptor p. Endocr
Rev
2005, 26: 465-478). The beneficial effects observed in the above mentioned
studies on the reduced CRC incidence could therefore depend specifically from
the Er13 activation.
The involvement of ER13 in the adenomatous polyposis and CRC is demonstrated
by its reduced expression, with respect to normal intestinal mucosa, in
polypectomized patients already in pre-cancerous stage (Di Leo A et al. ER-$
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
3
expression in large bowel adenomas: implications in colon carcino genesis. Dig
Liver Dis 2008, C40: 260-266). Significantly, ERI3 reduction relates with an
increased proliferation and a progressive cell de-differentiation,
demonstrating that
ERI3 silencing is involved in tumour progression. The colorectal pre-cancerous
lesions hence are early warnings of CRC development in a relevant part of the
population. The dramatic decline of ER6 is also observed in the more advanced
stages of the neoplastic transformation (Konstantinopoulos PA et al. Oestrogen
receptor beta (ER/3) is abundantly expressed in normal colonic mucosa, but
declines in colon adenocarcinoma paralleling the tumor's dedifferentiation.
Eur J
Cancer 2003, 39: 1251-1258).
Experimental studies conducted on C57BL/6J - APC Min/+ transgenic mice, that
carry a mutation of the germinal line of the APC gene, support the estrogens'
protective role in the prevention of the neoplastic transformation in colonic
epithelial cells. In particular, Weyant et al. (Weyant MJ et al. Reciprocal
expression
of ERa and ERP is associated with estrogen-mediated modulation of intestinal
tumorigenesis. Cancer Res 2001, 61: 2547-2551), using female transgenic mice,
demonstrated that intestinal adenomas spontaneously develop after ovariectomy.
Ovariectomy gave rise to a 77% increase in intestinal adenomas neoformation,
whereas the subsequent administration of 17-6-estradiol caused a reduction in
intestinal adenomas.
Besides genetic causes, it is known that exposure to carcinogens inside the
intestinal lumen or to agents potentially genotoxic for the epithelial cells
of
intestinal mucosa is an epigenetic event that facilitates the inactivation of
both
alleles or the somatic mutation of the APC gene, both in FAP and sporadic
form.
These dangerous substances are normally ingested with the diet, or they can be
formed in the intestinal lumen as an effect of the digestion, in particular of
fats, or
by degradation of bile acids.
For this reason, a diet rich in fibres, believed exerting a shielding effect
on the
intestinal mucosa or adsorbing potentially genotoxic xenobiotics, is
considered
useful =in CRC prevention (Robertson DJ et al. Fat, fiber, meat and the risk
of
colorectal adenomas. Am J Gastroenterol 2005, 100: 2789-2795). However, the
clinical evidences of such efficacy are not always convincing. This often
depends
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
4
on the poor quality of the various experimental protocols, where the expected
effects are not weighed against the total fibre dietary intake, comprised of
soluble
and insoluble fibres. Therefore, the expected effects due to the addition to
the diet
of a known amount of a fibre qualified for its structure, degree of solubility
and
digestibility, with its own viscosity and gelling properties in the intestinal
lumen, are
largely unclear. All the previously mentioned features (i.e. structure, degree
of
solubility and digestibility, viscosity and gelling properties) heavily affect
the
properties of the fibre, as well as its biological effects on the intestinal
physiology
of complex organisms (Jones JR et al. Dietary reference Intake: implication
for
fiber labeling and consumption: a summary of the International Life Sciences
Institute North America Fiber workshop, June 1-2, 2004 Washington, DC. Nutr
Rev
2006, 64: 31-38).
_SUMMARY OF THE INVENTION
According to the Inventors, the therapeutic need may be met by locally
delivering
agents capable to act as selective agonists to the estrogen receptor-beta
involved
in the progression of the adenopolyposis to colorectal cancer, significantly
reducing the systemic absorption of such agents and thus favouring their
pharmacological action onto the intestinal mucosa.
Compositions for oral administration comprising an association of at least one
phytoestrogen, selectively agonist to Estrogen Receptor Beta (ER(3), or more
phytoestrogens with the above properties, and insoluble dietary fibres, i.e.
fibres
resistant to enzymatic digestion in the intestinal tract, may meet the need in
the
medical field of tools useful for prevention or treatment of the
adenopolyposis coli
condition and its progression to colorectal cancer.
Therefore, in a first aspect it is an object of the present invention
compositions
comprising at least one phytoestrogen or a mixture of phytoestrogens
selectively
agonists to the estrogen receptor-beta (ERf3), and at least one insoluble and
indigestible fibre or mixtures thereof selected from the group consisting of
non-
starch polysaccharides.
Yet, it is a further object of the invention the use of such compositions
orally
administered for the topical treatment of the intestinal mucosa, and in
particular
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
the treatment of adenopolyposis coli conditions, and for the prevention of
their
progression to colorectal cancer.
As it will be readily apparent from the detailed description of the invention
reported
hereafter, in the presence of pre-cancer lesions of the colon characterised by
5 mutations of the APC tumour suppressor, defined as polyps or adenomas,
the
compositions for oral administration can be profitably used to reduce the
number
and volume of polyps and to prevent their progression toward the neoplastic
transformation, reducing their grade of dysplasia.
The compositions for oral administration object of the present invention can
be
profitably used to restore ERP expression onto the colon mucosa, otherwise
deficient or silenced when intestinal adenomas occur, and to restore a ratio
of
expression between the estrogen receptor beta and alpha in favour of the anti-
proliferative activity.
Moreover, the association from at least one phytoestrogen, selective for the
estrogen receptor-beta, and at least one insoluble dietary fibre forming the
compositions for oral administration object of the present invention
represents a
preferential delivery system for the ER8 selective phytoestrogen to the colon,
where the adenopolyposis is preferentially located, with an enrichment of the
components onto the intestinal mucosa and into the colonocytes. The oral
compositions object of the present invention are therefore a safe and
effective
delivery system for the topical treatment of the intestinal mucosa, in
conditions at
high risk for the development of adenomas and their progression to
adenocarcinoma, therefore useful in the treatment of subjects affected by
adenopolyposis coli, in familial and sporadic forms, recruited to colonoscopic
screening and after polypectomy, to prevent the development of advanced
adenomas, and to prevent their potential neoplastic transformation into
adenocarcinoma, also known as colorectal cancer (CRS).
BRIEF DESCRIPTION OF THE FIGURES
Figure 1. The figure shows the genic expression (Messenger RNA, mRNA) of
estrogen receptors in APC Mini+ mouse intestine. The levels of expression of
ER13
and ERa mRNA are expressed as optical density units in comparison with the
optical density units of constitutive 18S mRNA, relative to a structural
protein
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
6
unmodified in the experimental conditions of the present study. The results
show:
a significant increase of ER3 mRNA in the silymarin 200 ppm group (p=0.03),
with
respect to the control group fed standard diet; an unexpected significant
decrease
of the ERa mRNA in the group fed the insoluble fibre lignin alone (p = 0.04);
a
significant increase of ER 3 in the group fed the composition formed by the
association lignin+silymarin (p=0.04).
Figure 2. The figure shows the ratio between the mRNAs of estrogen receptor
alpha and beta, in the intestine of APC Mini-' mice. By comparison with the
group
of animals subcutaneously treated with estrogen (known to be non selectively
active on ER[3 and ERa), the results confirm the selectivity of silymarin for
ER3,
being the receptor increased by the ligand. Moreover, the results demonstrate
that
the association of silymarin (even at low doses) with the insoluble fibre
lignin, by
itself surprisingly active in reducing the expression of ERa which possesses a
proliferative activity, facilitates the restoration of an expression ratio
between the
estrogen receptors in favour of the anti-proliferative activity.
Figure 3. The figure shows the ratio between the level of estrogen receptor
alpha
and beta proteins, in the intestine of APC Min' mice, as detected by Western
Blotting. With respect to the control group of animals fed standard diet only,
an
increase of the ER3 protein versus the ERa protein is observed in animals fed
different diets, this increase being higher in the group subcutaneously
treated with
173-estradiol; in the silymarin fed group; in the lignin fed group; in the
group fed
the composition containing lignin + silymarin, even at low doses.
Figure 4. Figure 4A compares ER/ERa mRNA ratio in the small intestine of wild
type (WT) and APC Miegroups, fed different diets. Silymarin (SIL), lignin
(LIG)
and silymarin+lignin (SIL+LIG) restored ER/ERa mRNA to levels comparable
with WT healthy mucosa. ER[3 protein was also increased in all the dietary
managed groups (Fig. 4 B), when compared to controls.
Figure 5. TUNEL assay (A-C) and cleaved caspase-3 (CC-3) (D) assessment of
pro-apoptotic acivity in non adenomatous and adenomatous mucosa from APC
Min' animals fed the standard diet (Control) or different diets (SIL, LIG,
SIL+LIG),
in comparison with wild type (WT) mice fed the standard diet. In non-
adenomatous
mucosa, silymarin, lignin, and the combination of the two restored apoptosis
to
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
7
levels comparable with the healthy mucosa from WT mice. In adenomatous
mucosa, only the association of silymarin and lignin restored apoptosis to
values
comparable with healthy mucosa from WT mice. Whereas CC-3 markedly
decreased in the APC Min' mice fed the standard diet, a strikingly increase
was
observed in the dietary managed groups.
DETAILED DESCRIPTION
According to the state of the art described above, and considering the side
effects
potentially experienced with non selective agonists of estrogen receptors, the
oral
compositions object of the present invention comprise at least one
phytoestrogen
selectively agonist to estrogen receptor beta (ER(3), or mixtures of such
phytoestrogens, supported by a wide use that sustains its/their clear safety
and
effectiveness profile.
For the purpose of the present invention, the preferred phytoestrogens are
selected from the group consisting of flavolignans, namely silymarin,
silybinin, iso-
silybinin, silydianin, silychristin, the isoflavone genistein, the flavonoid
resveratrol,
coumestrol and mixtures thereof. The phytoestrogen or phytoestrogens composing
the mixture can be present in the composition both in their purified form and
as
plant extract. More preferably, the phytoestrogen is silymarin, as such or as
a Milk
Thistle extract, the most preferred one being the Milk Thistle extract
consisting of a
mixture of flavolignans silymarin, silybinin, iso-silybinin, silydianin and
silychristin.
It is known that silymarin, a standardized mixture of flavolignans extracted
from
Milk Thistle fruits, widely used in traditional medicine as hepatoprotectant,
possesses a documented profile of safety and tolerability, as well as
properties of
the same as selective ERI3 agonist, without any relevant activity on Era, have
been described (Seidlova-Wuttke D et al. Silymarin is a selective estrogen
receptor p (ERN agonist and has estrogenic effect in the metaphysis of the
femur
but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats. J
Steroid
Biochem Mol Biol 2003, 86: 179-188).
"Silymarin" is the common denomination used for a plant extract containing a
mixture of flavolignans: silymarin, silybinin, iso-silybinin, silydianin and
silychristin
in variable concentrations and ratios. In the compositions object of the
present
invention, "Silymarin" means the mixture of flavolignans composing the
extract, in
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
8
different concentrations and ratios, with particular reference to a Milk
Thistle
extract with an analytical profile characterised by a silymarin content higher
than
70% and a silybinin A+B content higher than 30%. In general, additional
components to and/or substitutes of silymarin in the compositions object of
the
present invention are other phytoestrogens, provided that they are selective
for
ER6 and with a anti-estrogenic activity, that is not inducing a significant
proliferative activity on tissues that are classical targets for the
estrogens, such the
above mentioned phytoestrogens, in similar concentrations as that of
silymarin.
The other essential component of the compositions for oral administration of
the
present invention is an insoluble and indigestible, i.e. resistant to
enzymatic
digestion in the gastrointestinal tract, fibre. The insoluble fibre can be
present in a
purified form or as component of a natural extract, provided that in the
compositions the insoluble fibre content is between 1% and 30%. Such fibre is
selected from plant fibres with a non-starch polysaccharidic nature and among
these fibres are preferably fibres selected in the group consisting of
polyphenylpropanoid lignin (hereafter called also lignin), cellulose,
resistant starch,
inulin and long chain inulin and mixtures thereof. Particular preference is
given to
the lignin. The insoluble fibre can be present as a purified component as well
as a
constituent of an extract. In the later case, the above mentioned insoluble
fibres
can be present as a mixture and associated with other nutritional substances.
In
particular, the fibres can be used for the compositions of the invention as
follows:
in the case of lignin, as such in the polydisperse form or as wheat bran; in
the case
of cellulose, as such or as a soy extract; in the case of inulin, long chain
inulin is
preferable, with a polymerisation degree of 10-65 and an average chain length
of
25, as such or as artichoke extract, chicory extract or Dandelion root powder.
The fibres present in the oral compositions object of the present invention
are
anyway to be considered add-ons to the diet, but independent from the total
dietary fibre intake.
The compositions according to the inventions have shown unexpected biological
properties, since said compositions, characterized substantially by the
association
from at least one phytoestrogen, selectively agonist to estrogen receptor beta
(ERI3), or mixtures thereof and at least one dietary insoluble fibre selected
from
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
9
fibres having a non-starch polysaccharidic nature or mixtures thereof, proved
to
have a synergistic effect on the parameters used for the necessary
experimental
validation of their usefulness.
In fact, the dietary insoluble fibre (in particular lignin) proved to be
active in
maintaining ERI3 proteic expression, evidence unknown to date, and proved to
be
synergic with the phytoestrogen silymarin in significantly keeping under
control
parameters that are markers of the proliferation and neoplastic progression,
such
as for example the volume and degree of dysplasia of adenomatous polyps.
In addition similar synergistic unexpected effects between phytoestrogens and
fibres have been seen in other relevant biological parameters, such as the
restoration of a pro-apoptotic activity on the adenomatous mucosa and even
more
interestingly on the non-adenomatous mucosa, to level comparable with those
observed on healthy intestinal mucosa. The unbalanced proliferation/apoptosis
ratio observed on the non adenomatous intestinal mucosa of APC Min" mice fed
the standard diet ¨ an experimental model validated to assess both the
pathobiological mechanisms as well as the efficacy of pharmaceutical and/or
nutraceutical interventions of human clinical relevance ¨ can explain the
clinically
documented recurrence of polyps in patients entered the screening colonoscopy
program, because of previous polyp detection and polypectomy, and regarded as
at increased risk of CRC development and progression.
The results obtained above mentioned in summary widely support the envisaged
use of the compositions object of the present invention. In particular, in
mammals,
humans or non-humans, a composition for oral administration according to the
invention can induce the expression of the estrogen receptor beta directly on
the
intestinal mucosa, when such receptor is poorly expressed or absent because of
the presence of pre-cancerous lesions in the colon mucosa, due to a mutation
of
the APC tumoral suppressor, such as per familial (FAP) and sporadic
adenopolyposis.
In addition, the oral compositions according to the present invention could be
a
useful system to preferentially target the delivery of the phytoestrogens to
the
intestinal area affected from polyp development, being this area the small
intestine
in the experimental mouse model and the colon in humans, where the insoluble
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
fibres are partially digested. The insoluble fibres contained in the
compositions
according to the present invention, and particularly lignin, act as a shield
in the
upper gastrointestinal tract, where phytoestrogens are otherwise
preferentially
absorbed. Moreover, this shielding effect allows a prolonged contact of the
5 phytoestrogens comprised in the compositions according to this invention
onto the
intestinal mucosa and onto colonocytes. As a proof of concept, whereas the
insoluble fibre, and particularly lignin, was per se ineffective in
counterfighting
intestinal neoplasia, as assessed by the number of developed polyps and their
volume, the compositions according to the invention, and particularly the
10 combination of silymarin at the lowest effective dose with lignin
determined a
maximal reduction in polyp number and volume, comparable with the one obtained
by adding the standard diet with silymarin at the highest effective dose.
Compositions according to the invention can therefore usefully be employed,
either as pharmaceutical products or nutraceuticals, in the treatment of
patients
affected by colon adenomas, diagnosed through colonoscopic examination, with
the aim of reducing polyp number and volume, of preventing their progression
to
advanced adenomas and, possibly, to adenocarcinoma. Compositions according
to the invention can also be employed to prevent or reduce the development of
new polyps and to prevent their progression to an advanced form, and possibly
to
adenocarcinoma, in polypectomised patients currently recruited to screening
colonoscopy program, in the period between scheduled screening colonoscopies.
The compositions for oral administration of the present invention can be in
both
liquid and solid form. Independently from the type of phytoestrogens used and
from the form thereof (i.e in purified form or as extract), in said
compositions the
phytoestrogens and the mixtures thereof are comprised from 0.1% to 10% by
weight, more preferably from 0.5% to 5%, and most preferably from 1% to 2%.
In fact, when the phytoestrogen is silymarin, said solid and liquid oral
compositions
preferably comprise from 0.1% to 10% by weight, more preferably from 0.5% to
5%, and most preferably from 1 % to 2% of silymarin, independently from the
extract thereof used.
In the case of use of genistein as phytoestrogen, the solid and liquid
compositions
of the present invention preferably comprise from 0.1% to 10% by weight, more
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
11
preferably from 0.5% to 5%, and most preferably from 1% to 2% of genistein,
independently from the extract used.
The solid and liquid compositions object of the present invention preferably
comprise from 0.1% to 10% by weight, more preferably from 0.5% to 5%, and
most preferably from 1% to 2% of coumestrol, independently from the extract
used.
The solid and liquid compositions object of the present invention preferably
comprise from 0.1% to 10% by weight, more preferably from 0.5% to 5%, and
most preferably from 1% to 2% of mixed phytoestrogens, independently from the
extract used.
With reference to the insoluble fibre component, the solid compositions of the
present invention preferably comprise from 1% to 30% by weight, more
preferably
from 5% to 25%, and most preferably from 10% to 20% of indigestible dietary
fibre, independently from the type of extract used (i.e. purified or as such).
The liquid compositions of the present invention preferably comprise from 1%
to
20%, more preferably from 2% to 15%, and most preferably from 5% to 10% of
indigestible and insoluble dietary fibre, independently from the type of
extract used
(i.e. purified or as such).
The solid compositions can be in form of powder, effervescent powder or
chewable tablets. The powder forms can in turn be multi-dose (bottles,
canisters,
jars) and single dose (sachets) packages. The liquid forms can be in form of
syrups, solutions, suspensions or aqueous dispersions. In such formulations,
the
compositions can additionally comprise acceptable pharmaceutical or food grade
excipients, diluents, preservatives, flavours, foaming agents, pH correcting
agents,
etc., depending on the chosen form, suitable for the oral administration.
Moreover, the compositions of the present invention can further comprise
probiotics, such as for example lactobacilli and/or bifidobacteria, both live
and
tyndalized, with the purpose of contributing to the normalization of the
intestinal
microflora and to the intestinal fermentation of the fibre, effects known
contributing
to the formation of a healthy microenvironment in this anatomical district.
Probiotics are added as adjuvants to maintain or balance the intestinal
physiology
and to help metabolise the indigestible and insoluble fibre.
CA 02714668 2016-03-02
12
Compositions in accordance with the present invention are shown in working
examples 1-10. Working examples 1-7 refer to solid formulations, and working
examples 8-10 to liquid formulations. Unless otherwise specified, the
proportions
of the components comprising the compositions in the working examples
represent the weight percentages of the respective components relative to the
final
product. The following examples further describe and demonstrate embodiments
within the scope of the present invention. The scope of the claims should not
be
limited by the preferred embodiments and examples, but should be given the
broadest interpretation consistent with the description as a whole.
Solid formulations
Example 1: Effervescent powder
Component Quantity %
Milk Thistle Dry Extract 70% HPLC silymarin 2.00
Corresponding to silymarin 1.40
Lignin 20.00
Maltodextrins 70.90
Sodium Citrate 4.50
Potassium Citrate 0.50
Citric Acid 1.00
Silicon Dioxide 0.10
Flavouring 1.00
Example 2: Effervescent powder
Component Quantity /.3
Milk Thistle Dry Extract 70% HPLC silymarin 2.00
Corresponding to silymarin 1.40
Oligosaccharide Fibre (Inulin) 20.00
Maltodextrins 70.90
Sodium Citrate 4.50
CA 02714668 2010-08-12
' WO 2009/103788
PCT/EP2009/052038
13
Potassium Citrate 0.50
Citric Acid 1.00
Silicon Dioxide 0.10
Flavouring 1.00
Example 3: Effervescent powder
Component Quantity %
Milk Thistle Dry Extract 70% HPLC silymarin 2.00
Corresponding to silymarin 1.40
Lignin or Long Chain lnulin 20.00
Lactobacillus Acidophilus, Tyndalised
Equivalent to 10 MLD
Maltodextrins 71.90
Sodium Bicarbonate 2.60
Tartaric Acid 1.40
Silicon Dioxide 0.10
Flavouring 2.00
Example 4: water-dispersible powder
Component Quantity %
Silymarin 1.40
Dandelion Root Powder 35.00
Maltodextrins 61.50
Silicon Dioxide 0.10
Flavouring 2.00
Example 5: Effervescent powder
Component Quantity %
Milk Thistle Dry Extract 70% HPLC silymarin 1.00
Corresponding to silymarin 0.70
Genistein 0.70
Dietary or Oligosaccharidic Fibre (lnulin) 20.00
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
14
Maltodextrins 70.90
Sodium Citrate 4.60
Potassium Citrate 0.50
Citric Acid 1.00
Silicon Dioxide 0.10
Flavouring 1.00
Example 6: Effervescent powder
Component Quantity %
AlfaAlfa Dry Extract 10% HPLC coumestrol 7.00
Corresponding to coumestrol 0.70
Wheat Bran 30.00
Maltodextrins 55.90
Sodium Citrate 4.50
Potassium Citrate 0.50
Citric Acid 1.00
Silicon Dioxide 0.10
Flavouring 1.00
Example 7: water-dispersible powder
Component Quantity %
Silymarin 0.70
Genistein 0.70
Dandelion Root Powder 35.00
Maltodextrins 61.50
Silicon Dioxide 0.10
Liquid formulations
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
Example 8: Syrup
Quantity in 100 ml
Component Grams
Silymarin 0.90
Lignin, Cellulose or Inulin 10.00
Potassium Sorbate 0.10
Ascorbic Acid 0.50
Citric Acid, Anhydrous 0.05
Fructose 35.00
Flavouring 0.35
Water Q.S.
Example 9: Syrup
Quantity in 100 ml
Component Grams
Silymarin 0.45
Genistein 0.45
Lignin, Cellulose or Inulin 10.00
Potassium Sorbate 0.10
Ascorbic Acid 0.50
Citric Acid, Anhydrous 0.05
Fructose 35.00
Flavouring 0.35
Water Q.S.
5 Example 10: Syrup
Quantity in 100 ml
Component Grams
Milk Thistle Dry Extract 70% HPLC silymarin 1.38
Corresponding to silymarin 0.90
Dandelion Root Powder 20.00
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
16
Potassium Sorbate 0.10
Sodium Benzoate 1.0
Ascorbic Acid 0.5
Citric Acid 0.15
Sorbitol 20.00
Saccharin 0.013
Flavouring 0.20
Purified Water Q.S.
Experimental part
The C57BL/6J APC Min/+ transgenic mouse is an excellent animal model for FAP,
because the mutated APC gene is homologous to the human one. Even in the
most common form of CRC, called sporadic, 85% of cases show the somatic
mutation of the APC tumour suppressor gene. Therefore, the APC mutated
transgenic animal model is acknowledged as the most significant for the study
of
the pathogenetic mechanisms that characterise the adenomatous polyposis in the
colon, both in FAP and sporadic form, and it is considered a validated animal
model for the set up of nutritional and pharmacological interventions aimed at
controlling the development of adenomas and at preventing their progression to
CRC (Levy DB et al. Inactivation of both APC alleles in human and mouse
tumors.
Cancer Res 1994, 54: 5953-5958; Paulsen JE et al. Qualitative and quantitative
relationship between dysplastic aberrant crypt foci and tumorigenesis in the
Mini+
mouse colon). For this reason, in setting up the oral formulations object of
the
present invention, and in the evaluation of their safety and efficacy, the
Inventors
made use of the above mentioned C57BL/6J APC Min/+ transgenic mouse model.
Hereafter are described the data showing the effect in C57BL/6J - APC Min/+
transgenic mice, orally fed silymarin added diets, containing soluble and
insoluble
fibres in different proportions with the purpose of highlighting the
differentiative
properties of the insoluble and indigestible fibre.
The three diets under examination, formulated with the aim of mimicking a fat
rich
dietary regimen, were as follows:
CA 02714668 2010-08-12
WO 2009/103788 PCT/EP2009/052038
17
= Diet 5K20 [Mucedola Srl, Settimo Milanese (Ml)], containing 4.50% of
total
fibre, composed of soluble and insoluble fibres;
= Purified diet containing 6.24% of insoluble fibre, constituted by lignin;
= Purified diet containing 6.24% of soluble fibre, constituted by Plantago
ovata
husk.
Silymarin up to 200 mg/kg was added to each diet. The diets were orally
administered for 10 weeks to 114 male C57BL/6J - APC Min/+ transgenic mice 5-6
weeks old. These mice have a mutation of the APC gene, and are prone to
develop colon adenomatous polyposis. Objective of the study was to verify the
capacity of the composition according to the present invention in
significantly
reducing polyps development and preventing their progression to severely
dysplastic forms, markers of neoplastic transformation, in an animal model
recognised as comparable to the human pathologic situation. The statistical
analysis has been performed by means of the One-way Analysis of Variance and
the t-Student tests, considering statistically significant a p<0.05.
The animals were divided into 14 groups, as reported in Table 1. Every oral
treatment lasted 10 weeks. The treatment scheme was designed to highlight the
effects of the type of fibre, associated or not with increasing amounts of
silymarin.
As a positive control, a group of transgenic mice fed standard diet (5K20,
Mucedola) and subcutaneously implanted with a pellet containing 1.5 mg of 1713-
estradiol (estrogen) was used.
Table1. Number of animals per group (sil= silymarin, ppm=part per million)
Standard diet Diet with Plantago Diet with lignin
ovata husk
+ sil 0 ppm 15 10 10
+ sil 10 ppm 6 6 6
+ sil 50 ppm 6 6 6
+ sil 200 ppm 15 6 6
+ sil 600 ppm 7
+ estrogen (s.c., control) 9
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
18
No difference in the daily dietary intake (about 3+0.1 g/day) was reported
among
animals in the different groups. During the treatment period, the mortality
rate was
low in the groups fed standard diet or diet added with compositions described
in
this patent application (7.1%), whereas in groups fed diet added with Plantago
ovata husk the mortality was very high (>50%).
Table 2 list the means and standard deviations of the weight of the animals
from
different diet groups, at time of sacrifice. At admission to the animal house
their
average weigh was 19 1.2 g.
Table 2. Mean and standard deviation of body weights at time of sacrifice
Standard diet Diet with lignin
-
+ sil 0 ppm 22.0 + 3.8 g 25.0 +
1.9 g
+ sil 10 ppm 26.0 + 1.9 g 25.2 +
2.3 g
+ sil 50 ppm 24.6 + 3.3 g 26.9 + 2.1 g
+ sil 200 ppm 23.5 + 2.6 g 27.9 + 1.7 g
+ sil 600 ppm 24.3 + 2.4 g -
+ estrogen (s.c., control) 24.9 + 2.8 g
Differently from animal groups fed the diet containing P. ovata husk soluble
fibre,
in which a high mortality rate and no reduction in polyp numbers were
observed,
the association of silymarin and lignin constituting one of the compositions
according to the present invention proved to be safe and well tolerated, and
resulted highly effective in keeping down the number, volume, and grade of
dysplasia of adenomatous polyps in the C57BU6J - APC Min/+ transgenic mouse
model. In addition, the dietary insoluble fibre (in this case lignin) proved
to be
active in maintaining EIR8 proteic expression, evidence unknown to date, and
proved, to be synergic with silymarin in significantly keeping under control
parameters that are markers of the proliferation and neoplastic progression,
such
as for example the volume and degree of dysplasia of adenomatous polyps.
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
19
After 10 weeks of treatment the animals received an intraperitoneal injection
of
0.75 mg of Bromodeoxyuridine (BrdU), equivalent to 30 mg/kg, to verify the
migration of cells of the intestinal mucosa along the villus axis (from crypt
at the
bottom to the luminal tip). This parameter allows to verify the normal
esfoliative
physiology of the intestinal mucosa, through which the mucosa keeps itself
composed of healthy and vital cells.
To this end, the animals were sacrificed 24, 48 and 72 hours after injection.
Small
intestine and colon were taken from every sacrificed animal. The small
intestine
was divided into three sections: proximal, medial and distal. The proximal
tract
was further divided in two portions that were subsequently scraped. One of the
two
was dipped in RNAlater and stored at -20 C and the other stored in liquid
nitrogen. The two samples were used for Real Time PCR and Western Blotting,
respectively. The medial and distal tracts, together with the colon, were used
for
the histological analysis. After a 3-hours pre-fixative treatment with formol,
the
intestinal tracts under examination were observed under an STM1
stereomicroscope, 3x magnification. Two blinded observers measured the number
and size of polyps.
Table 3 lists mean and standard deviation (SD) of the number of polyps
observed
in the animals fed the different diets. It has to be noticed that silymarin
added at
200 ppm to the standard diet significantly reduces the number of polyps
(p=0.005),
at a level comparable with the reduction observed in the transgenic mice of
the
control group, subcutaneously treated with estradiol. Lignin alone is
ineffective on
this parameter, but the association of lignin and silymarin, object of the
present
invention, significantly reduces the number of polyps, at a silymarin dose (50
ppm)
four times lower than that required to obtain the same results with standard
diet
(200 ppm).
CA 02714668 2010-08-12
WO 2009/103788 PCT/EP2009/052038
Tabella 3. Number of intestinal polyps in animals fed different diets
Standard diet Diet with Plantago Diet with lignin
+ sit 0 ppm 54.8 + 20.2 43.6 + 9.5 46.8 + 14.0
+ sit 10 ppm 44.0 + 21.8 45.4 23.8 43.8 + 19.0
+ sit 50 ppm 55.4 + 26.2 51.5 + 20.5 34.0 + 10.7*
+ sit 200 ppm 37.2 + 9.0* 50.0 + 4.7 48.5 + 2.5
+sil 600 ppm 52.6 + 24.6
Estrogen 32.33 + 12.06*
(control)
Table 4 lists the silymarin content (expressed as pg/g silybinin in the
tissue,
5 determined by HPLC) in the duodenal tract, where silymarin is known to be
preferentially absorbed, and in the ileum after seven days feeding 200 ppm
silymarin, or a composition containing 200 ppm silymarin and a non starch
polysaccharidic fibre (lignin) as an add-on to the standard diet of C57BL/6J
mice
(n=6). The association of silymarin and insoluble fibre caused a preferential
10 transport of the phytoestrogen in the ileal region, the intestinal area
where polyps
tipically develop in the transgenic mouse. Moreover, it is known that such
condition
mimics the development of adenopolyposis in human colon. Therefore, the
compositions object of the present invention can be an effective system for
the
topical treatment of the area affected by adenomatous formations.
15 Tabella 4. Mean and standard deviation of silymarin tissue concentration
in mouse
intestine
Duodenum (pg/g) Ileum (pg/g)
Silymarin 200 ppm, 7 days 6.54 0 2.34 2.84 II 2.03
Silymarin 200 ppm + Lignin, 7 days 2.47 El 2.38 3.13 0 2.71
Table 5 lists mean and standard deviation (SD) of the volume of intestinal
polyps.
Assuming polyps shape as a sphere, by measuring their diameter it was possible
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
21
to calculate their volume, expressed in mm3. Surprisingly, lignin alone is
able to
reduce polyps volume (p=0.0001). The association of silymarin with lignin is
able
to significantly reduce the volume of polyps (p=0.0001). Moreover, the
association
is synergic for the two components, as suggested by the fact that the using
lower
doses of phytoestrogen, the same effect as per the higher doses of single
component is observed. Noteworthy, estradiol proved to be ineffective on this
parameter, demonstrating that the composition object of the present invention,
containing a phytoestrogen selectively agonist to ER13, is effective on this
parameter.
Table 5. Comparison of polyps volume (mm30 SD) in animal fed the different
diets
Standard diet Diet with lignin
+ sil 0 ppm 242,1 105.1 92.3 61.9*
+ sil 10 ppm 145.0 100.6 121.0
72.6
+ sil 50 ppm 158.4 60.3 99.00
53.13*
+ sil 200 ppm 120.2 69.0* 138.0
63.3
+ sil 600 ppm 162.07 89.35
Estrogen (control) 141.78 79.1
Histological preparations of randomly chosen intestine sections of every
animal
from the different treatment groups were observed by a blinded pathologist,
who
graded the dysplasia of the adenomatous formations present as minor, mild or
severe. In the estradiol-treated animals, 70% showed polyps with dysplasia
classifiable as severe, versus 21.4% in animals fed standard diet added with
200
ppm silymarin, 30% in animals fed diet with lignin, and 20% in animals fed
diet
with lignin added with 50 ppm silymarin.
Table 6 lists the results concerning HLC (highest labeled cell) in the
experimental
groups. Data shows that cell migration rate, and consequently the esfoliation
rate
of enterocytes in the intestinal lumen, is significantly increased in the
group treated
with lignin and silymarin (even at low doses).
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
22
Table 6. Percentage of colonocytes migration from the crypt to the apex of the
villus in transgenic animals of the different groups
24 hours migration (%)
Standard diet 28 + 2.6
+ estrogen 47.3 + 10.5*
+ sit 200 ppm 46.6 + 7.0*
4- lignin 35 13.8
+ (Lignin + sit 50 ppm) 44.4 + 11.8*
With regard to the mechanism of action of the association silymarin and
lignin,
data demonstrates for the first time a potentiation of the ER8 expression on
the
intestinal mucosa. RT-PCR results are shown in Figure 1. The levels of
expression
of messenger RNA for ER8 and ERa are reported as average ratio between the
optical density of the messenger for each receptor and that of 188 rRNA,
relative
to 8-actin, a structural protein that is unmodified in the experimental
conditions of
the study.
The results show a significant increase of ER8 mRNA for in the silymarin 200
ppm
group (p=0.03), with respect to the group fed standard diet.
Surprisingly, the Inventors demonstrated for the first time that the ERa mRNA
is
significantly decreased in the group treated with the insoluble fibre
(p=0.04); the
reduction is more pronounced in the group fed with a composition containing
the
association silymarin-lignin (p=0.04). From comparison with the group
subcutaneously treated with estrogen (active on both ER8 and ERa), data
confirms silymarin as selective ligand to ER8 and demonstrates that the
association of silymarin (even at low doses) and lignin - the latter
surprisingly
active in reducing expression of ERa known to exert proliferative properties -
further facilitates the re-establishment of a ratio between the two estrogen
receptors in favour of the antiproliferative activity, as shown in Figure 2
and
demonstrated by the data in Tables 3-6.
CA 02714668 2010-08-12
WO 2009/103788
PCT/EP2009/052038
23
Figure 3 shows the level of intestinal expression of the estrogen receptors,
as ratio
between ER6 and ERa proteins, determined using the Western Blotting method.
Compared to the group of animals fed standard diet only, an increase of ER (3
as a
protein in comparison to ERa protein was observed, and this increase is more
marked in the group subcutaneously treated with 176-estradiol, thus confirming
the protective role hypothesised for the estrogens; in the silymarin-treated
group,
thus confirming its properties as a phytoestrogen selective to ER13; and,
surprisingly, in both groups treated with lignin and with lignin + silymarin,
even at
low doses.
Additional experimental were collected in order to provide evidence of: A)
altered
proliferative and apoptotic activities even on the non adenomatous mucosa of
APC
Min/+ animals, in comparison with syngeneic wild type (WT), no APC mutated,
C57BL/6J intestinal mucosa (regarded as normal and healthy), being both animal
groups fed the standard diet; B) the capability of the oral compositions
object of
the present invention to restore ER6 expression, proliferative and apoptotic
activity
in APC Min/+ mice, to levels comparable to the ones observed onto the normal
mucosa of WT animals fed the standard diet. Therefore, these evidences further
support the use of such oral compositions as an useful adjunct to screening
colonoscopy program in previously polipectomised patients, at increased risk
of
developing new polyps (recurrence). Figure 4 (A, B) shows the ratio between
ER6
and ERa mRNAs and the level of expression for both receptors as a protein,
onto
the non-adenomatous mucosa of WT and control APC Min/+ fed the standard diet,
or APC Min/+ fed different diets. Figure 5 (A-D) demonstrates that: i) the non
adenomatous mucosa of APC Min/+ mice fed the standard diet has lost pro-
apoptotic control on cell proliferation when compared to the WT mice fed the
standard diet, as detected by markers of apoptosis, such as the reduced number
of positive cells on the TUNEL assay and cleaved capsase 3 protein expression,
ii)
the oral compositions object of the present invention, with particular
reference to
the association of silymarin and lignin, restore apoptotic control on cell
proliferation
to levels similar with the ones observed onto the normal, healthy intestinal
mucosa
of WT mice.
